Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) announced an inducement equity grant for its new Chief Operating Officer, Dr. Aggarwal. The Compensation Committee approved non-qualified stock options to purchase 400,000 shares outside the 2021 Omnibus Plan.

The option was granted effective April 27, 2026 at an exercise price of $1.72 per share (closing price on the grant date) and vests over four years: 25% after 12 months, then monthly over 36 months, subject to continued employment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Grant aligns new COO incentives: 400,000 options issued to Dr. Aggarwal
• Vesting schedule encourages multi-year retention: 25% after 12 months, then monthly over 36 months

Negative

• Issuance of 400,000 options creates potential future dilution for existing shareholders

News Market Reaction – CRDF

-3.57%

-3.57% News Effect

On the day this news was published, CRDF declined 3.57%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement details a standard inducement grant of 400,000 stock options at an exercise price ...

Analysis

This announcement details a standard inducement grant of 400,000 stock options at an exercise price of $1.72 for the new COO under Nasdaq Rule 5635(c)(4), vesting over 4 years. It follows earlier leadership and option-grant disclosures and fits into a broader governance and incentive refresh. Investors may monitor how this revamped team advances onvansertib programs, upcoming data presentations, and any further equity plan changes highlighted in recent proxy materials.

Key Figures

Inducement option grant: 400,000 shares Exercise price: $1.72 per share Initial vesting cliff: 25% after 12 months +5 more

8 metrics

Inducement option grant 400,000 shares Non-qualified stock options granted to new COO under Nasdaq Rule 5635(c)(4)

Exercise price $1.72 per share Closing price on April 27, 2026, used for inducement option grant

Initial vesting cliff 25% after 12 months Portion of COO inducement options vesting after first year of employment

Remaining vesting period 36 months Monthly vesting schedule for remaining COO options after first year

Total vesting term 4 years Overall vesting duration for COO inducement stock options

Current share price $1.72 CRDF pre-news price level used as option exercise price benchmark

52-week high discount 62.24% below high Price vs. 52-week high of $4.555 before inducement grant announcement

Market capitalization $117,596,221 Equity value before reporting COO inducement grant

Historical Context

5 past events · Latest: Apr 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	KOL webinar CMML	Positive	+0.0%	Announcement of KOL webinar on CMML single-agent onvansertib data.
Apr 21	Phase 2 data update	Positive	-7.3%	Plan to present updated Phase 2 onvansertib data in mCRC at ASCO 2026.
Apr 17	Preclinical combo data	Positive	-1.1%	Preclinical AACR data on onvansertib plus HER2-targeted ADC in breast cancer models.
Apr 09	Leadership changes	Neutral	-5.4%	Appointment of new CEO, CFO, and COO with associated inducement option grants.
Mar 20	KOL webinar mCRC	Neutral	-1.1%	Announcement of KOL webinar focused on first-line RAS-mutated mCRC data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally been clinical or management-positive, yet shares often showed flat or negative next-day moves, indicating a pattern of muted or adverse price reactions to ostensibly constructive updates.

Recent Company History

Over recent months, Cardiff Oncology has focused updates on its PLK1 inhibitor onvansertib and leadership changes. Events include KOL webinars on CMML and first-line RAS-mutated mCRC, preclinical data showing strong activity in HER2-low breast cancer, and executive appointments with sizeable option grants, such as 486,650-share awards at exercise prices around $1.58. Despite these developments, 24-hour price reactions around prior announcements ranged from 0% to about -7.3%, suggesting cautious market reception to both clinical and corporate news. Today’s inducement grant fits into this pattern of incremental governance and compensation updates.

Regulatory & Risk Context

Short Interest: 28.18%

Short Interest

28.18% of shares outstanding

as of 2026-05-29 Days to cover: 12.28

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, equity incentive plan

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to Dr. Aggarwal becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"approved the grant of non-qualified stock options to purchase 400,000 shares of Cardiff Oncology common stock"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"has an exercise price of $1.72 per share, the closing price on the grant date."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced that in connection with Dr. Aggarwal joining Cardiff Oncology as Chief Operating Officer, the Company’s Compensation Committee approved the grant of non-qualified stock options to purchase 400,000 shares of Cardiff Oncology common stock outside of the Cardiff Oncology 2021 Omnibus Equity Incentive Plan. The stock option was granted as an inducement material to Dr. Aggarwal becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The option was granted as of April 27, 2026, and has an exercise price of $1.72 per share, the closing price on the grant date. The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to Dr. Aggarwal’s continued employment with Cardiff Oncology on such vesting dates.

About Cardiff Oncology, Inc. 
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients. 

For more information, please visit https://www.cardiffoncology.com. 

Investor Contact: 
Candice Masse 
astr partners 
candice.masse@astrpartners.com 

Media Contact:  
Amy Bonanno 
Lyra Strategic Advisory 
abonanno@lyraadvisory.com 
  

FAQ

What did Cardiff Oncology (CRDF) grant to the new COO on April 27, 2026?

Cardiff Oncology granted non-qualified options for 400,000 shares to the new COO. According to the company, the grant was an inducement under Nasdaq Listing Rule 5635(c)(4) and was completed outside the 2021 Omnibus Equity Incentive Plan.

What is the exercise price and grant date for CRDF's inducement option to Dr. Aggarwal?

The option was granted on April 27, 2026 with an exercise price of $1.72 per share. According to the company, $1.72 was the closing price on the grant date and sets the strike for the options.

How does the vesting schedule work for the 400,000 CRDF options granted to the COO?

The options vest over four years: 25% after 12 months, then monthly over the next 36 months. According to the company, vesting is subject to the COO's continued employment on each vesting date.

Why did Cardiff Oncology use an inducement grant outside the 2021 Omnibus Plan for CRDF options?

Cardiff Oncology used an inducement grant to recruit the new COO under Nasdaq rules for new hires. According to the company, the grant complies with Nasdaq Listing Rule 5635(c)(4) as an employee inducement award.

Will the 400,000-option grant to the CRDF COO dilute existing shareholders?

The option grant creates potential future dilution if exercised, depending on outstanding shares. According to the company, the award is exercisable at $1.72 and will only dilute if and when options are exercised.